Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long‑term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report

Fukaya,Raita; Ozaki,Masatoki; Kamamoto,Dai; Tokuda,Yukina; Kimura,Tokuhiro; Fukuchi,Masahito; Fujii,Koji

doi:10.3892/mco.2016.996

October-2016 Volume 5 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2016 Volume 5 Issue 4

Full Size Image

Case Report

Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long‑term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report

Authors:
- Raita Fukaya
- Masatoki Ozaki
- Dai Kamamoto
- Yukina Tokuda
- Tokuhiro Kimura
- Masahito Fukuchi
- Koji Fujii
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Shizuoka City Shimizu Hospital, Shizuoka 424‑8636, Japan, Department of Radiation Oncology, Shizuoka City Shimizu Hospital, Shizuoka 424‑8636, Japan, Department of Neurosurgery, Keio University School of Medicine, Tokyo 160‑8582, Japan, Department of Pathology, Keio University School of Medicine, Tokyo 160‑8582, Japan
Pages: 417-421
|
Published online on: August 17, 2016

https://doi.org/10.3892/mco.2016.996
Expand metrics +

Abstract

The prognosis of recurrent and disseminated glioblastoma is very poor. Bevacizumab is an effective established therapy for recurrent glioblastoma following treatment with radiotherapy plus temozolomide. However, the efficacy of bevacizumab is limited to prolonging progression‑free survival, without significant prolongation of the overall survival. We herein report a case of glioblastoma in a 32‑year‑old female patient with encephalocraniocutaneous lipomatosis (ECCL) that had disseminated following surgical resection and subsequent treatment with temozolomide and radiation therapy. The disseminated tumors disappeared completely after five courses of bevacizumab therapy. Surprisingly, the patient has remained in clinical remission for >2.5 years after dissemination by continuing this therapy. To the best of our knowledge, this is the first case of long‑time clinical remission following glioblastoma dissemination and treatment with bevacizumab. In the present case, bevacizumab exerted an atypically strong antitumor effect against disseminated glioblastoma after multidisciplinary treatments had already been applied. Moreover, this is the first report of ECCL associated with a malignant brain tumor.

View Figures

View References

1	Arita N, Taneda M and Hayakawa T: Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien). 126:84–92. 1994. View Article : Google Scholar : PubMed/NCBI
2	Awad I, Bay JW and Rogers L: Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery. 19:247–251. 1986. View Article : Google Scholar : PubMed/NCBI
3	Greenberg AD, Scatliff JH, Selker RG and Marshall MD: Spinal cord metastasis from bronchogenic carcinoma. A case report. J Neurosurg. 23:72–75. 1965. View Article : Google Scholar : PubMed/NCBI
4	Delattre JY, Walker RW and Rosenblum MK: Leptomeningeal gliomatosis with spinal cord or cauda equina compression: A complication of supratentorial gliomas in adults. Acta Neurol Scand. 79:133–139. 1989. View Article : Google Scholar : PubMed/NCBI
5	Moog U: Encephalocraniocutaneous lipomatosis. J Med Genet. 46:721–729. 2009. View Article : Google Scholar : PubMed/NCBI
6	Haberland C and Perou M: Encephalocraniocutaneous lipomatosis. A new example of ectomesodermal dysgenesis. Arch Neurol. 22:144–155. 1970. View Article : Google Scholar : PubMed/NCBI
7	Valera ET, Brassesco MS, Scrideli CA, de Castro Barros MV, Santos AC, Oliveira RS, Machado HR and Tone LG: Are patients with encephalocraniocutaneous lipomatosis at increased risk of developing low-grade gliomas? Childs Nerv Syst. 28:19–22. 2012. View Article : Google Scholar : PubMed/NCBI
8	Brassesco MS, Valera ET, Becker AP, Castro-Gamero AM, de Aboim Machado A, Santos AC, Scrideli CA, Oliveira RS, Machado HR and Tone LG: Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis. J Neurooncol. 96:437–441. 2010. View Article : Google Scholar : PubMed/NCBI
9	Phi JH, Park SH, Chae JH, Wang KC, Cho BK and Kim SK: Papillary glioneuronal tumor present in a patient with encephalocraniocutaneous lipomatosis: Case report. Neurosurgery. 67:E1165–E1169. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
11	Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P and Gruber ML: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 116:341–345. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long‑term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles